Sermorelin 10mg

Sermorelin is a synthetic 29-amino-acid peptide corresponding to the first 29 residues of the 44-amino-acid human growth hormone-releasing hormone (GHRH). These first 29 amino acids contain the full biological activity of native GHRH. Sermorelin was FDA-approved in 1997 under the brand name Geref for the diagnosis and treatment of growth hormone deficiency in children, making it one of the first peptides in this class to achieve regulatory approval. Sermorelin binds to the GHRH receptor (GHRH-R) on anterior pituitary somatotroph cells. Receptor activation triggers the Gs-adenylyl cyclase-cAMP-PKA signaling cascade, which promotes GH gene transcription, GH synthesis, and GH release from secretory granules. Importantly, sermorelin stimulates physiological pulsatile GH release rather than the constant elevation seen with exogenous GH administration. This preserves the normal feedback mechanisms and circadian GH secretion pattern. A key advantage of sermorelin over direct GH administration is that it works through the body's own regulatory system. The pituitary retains the ability to modulate GH output through somatostatin-mediated negative feedback, making GH overproduction unlikely. Research in aging populations has shown sermorelin can restore more youthful GH secretion patterns, improve sleep quality (particularly slow-wave sleep, which coincides with the major nocturnal GH pulse), and improve body composition.

Sermorelin is a synthetic 29-amino-acid peptide corresponding to the first 29 residues of the 44-amino-acid human growth hormone-releasing hormone (GHRH). These first 29 amino acids contain the full biological activity of native GHRH. Sermorelin was FDA-approved in 1997 under the brand name Geref for the diagnosis and treatment of growth hormone deficiency in children, making it one of the first peptides in this class to achieve regulatory approval. Sermorelin binds to the GHRH receptor (GHRH-R) on anterior pituitary somatotroph cells. Receptor activation triggers the Gs-adenylyl cyclase-cAMP-PKA signaling cascade, which promotes GH gene transcription, GH synthesis, and GH release from secretory granules. Importantly, sermorelin stimulates physiological pulsatile GH release rather than the constant elevation seen with exogenous GH administration. This preserves the normal feedback mechanisms and circadian GH secretion pattern. A key advantage of sermorelin over direct GH administration is that it works through the body's own regulatory system. The pituitary retains the ability to modulate GH output through somatostatin-mediated negative feedback, making GH overproduction unlikely. Research in aging populations has shown sermorelin can restore more youthful GH secretion patterns, improve sleep quality (particularly slow-wave sleep, which coincides with the major nocturnal GH pulse), and improve body composition.

Clinical studies in adults used 0.5-1.0 mg subcutaneously at bedtime. Pediatric GH deficiency protocols used 30 mcg/kg/day. Diagnostic testing used single IV bolus of 1 mcg/kg.

Store lyophilized (freeze-dried) powder at -20°C to 4°C in a dry environment protected from light. Unreconstituted peptide is stable for extended periods when stored properly.

Once reconstituted with bacteriostatic water or an appropriate solvent, store at 2-8°C and use within the timeframe specified on the Certificate of Analysis. Avoid repeated freeze-thaw cycles.

A Certificate of Analysis documenting purity, identity, and recommended storage conditions is included with every order.